Alvogen today announced the launch of the first generic equivalent of ZoladexTM in Central and Eastern Europe. The product will be marketed in two strengths (3.6mg and 10.8mg) under the brand name ReseligoTM and will be launched in Bulgaria, Croatia, Baltics, Romania, Hungary, Iceland and Poland from May 2016. Astra Zeneca‘s ZoladexTM, delivered sales of over EUR 200 million in Europe in 2015, according to IMS.
ReseligoTM contains the active ingredient goserelin and belongs to the class of GnRH agonists (analogues of gonadotropin releasing hormone) which interfere with the regulation of the sex hormone balance. As a consequence, testosterone levels are lowered in men and estradiol levels are lowered in women. This artificially induced lowering of hormone levels enables the symptomatic therapy of hormonesensitive tumors such as prostate cancer or breast cancer with goserelin. In addition, goserelin is used to treat certain benign gynecological disorders. Goserelin is administered in the form of a biodegradable implant which releases the active ingredient over a period of either one or three months.
Hacho Hatchikian, Executive Vice President at Alvogen in the CEE region, commented:
"We are delighted about the launch of ReseligoTM. This product represents an important milestone in the further development of our oncology portfolio in the region. After already being on the market in the CEE region with three biosimilar products, this is yet another first-to-market complex product in our portfolio, which reaffirms Alvogen’s leadership position in delivering difficult-to-make but affordable treatments to patients. ReseligoTM offers a more affordable – but equally effective – treatment option for cancer patients, offering compelling cost saving opportunities within the Central and Eastern European region."
ZoladexTM is a trademark of the AstraZeneca group of companies